The Wood on Clinuvel

By Dylan Bushell-Embling
Tuesday, 08 July, 2008

Clinuvel Pharmaceuticals [ASX: CUV] has set in train its plan to add international expertise to its board, with the appointment of a new non-executive director.

Jack Wood was appointed to the position today. Wood currently sits on the board of two Canadian biotechnology companies, Engene and QLT.

He also has experience in the Australian pharmaceutical sector, including eight years serving in various executive positons at CSL from 1992-2000.

Clinuvel is seeking international expertise in anticipation of the commercialisation of its photoprotective drug afamelanotide (CUV1647).

Related News

Babies of stressed mothers likely to get their teeth earlier

Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...

Customised immune cells used to fight brain cancer

Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...

Elevated blood protein levels predict mortality

Proteins that play key roles in the development of diseases such as cancer and inflammation may...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd